Paper
Paper
Search...
Search ResearchHub...
Ctrl+K
New
Home
Browse
Earn
Fund
RH Journal
Notebook
Lists
Leaderboard
RSC
USD
Changelog
Terms
Privacy
Issues
Docs
Support
Foundation
About
Phase I study of BMS-986299, an NLRP3 agonist, as monothe... | ResearchHub
Paper
Paper
Search...
Search ResearchHub...
Ctrl+K
New
Home
Browse
Earn
Fund
RH Journal
Notebook
Lists
Leaderboard
RSC
USD
Changelog
Terms
Privacy
Issues
Docs
Support
Foundation
About
Phase I study of BMS-986299, an NLRP3 agonist, as monotherapy and in combination with nivolumab and ipilimumab in patients with advanced solid tumors
0
Authors
Blessie Nelson
11 more
Blessie Nelson
•
Shaun O’Brien
9 more
•
Sarina Piha‐Paul
Published
January 1, 2025
Paper
Conversation
0
Reviews
0
Bounties
0
Sign in to review
Share your thoughts on this paper...
Best
Supporters
Support the authors with ResearchCoin
Tip RSC
Journal
Journal for ImmunoTherapy of Cancer
Topics
Medicine
Cancer Oncology
Internal Medicine
Psychiatry And Mental Health
Nivolumab
Show all topics
DOI
10.1136/jitc-2024-010013
License
CC-BY-NC-ND
Supporters
Support the authors with ResearchCoin
Tip RSC
Journal
Journal for ImmunoTherapy of Cancer
Topics
Medicine
Cancer Oncology
Internal Medicine
Psychiatry And Mental Health
Nivolumab
Show all topics
DOI
10.1136/jitc-2024-010013
License
CC-BY-NC-ND
